GSK, GlycoVaxyn collaborate on bacterial vaccine development

12/20/2012 | Genetic Engineering & Biotechnology News

GlaxoSmithKline Biologicals and GlycoVaxyn agreed to use the latter's bioconjugation technology to develop novel bacterial vaccines. The deal, which covers a set of pathogen targets, gives GSK an exclusive licensing option. GSK will give GlycoVaxyn an upfront payment and equity investment plus milestone fees and royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care